On October 20, OpenAI announced it had acquired Orchestra Bio, a four-year-old AI drug discovery startup that last raised $20 million in venture funding last year, and released GPT Rosalind as a full commercial product alongside the Rosalind Workbench agent suite. Orchestra's agents streamline lab tasks like monitoring compound manufacturing and tracking drug trials, and its team will work on GPT Rosalind, which moves from an April research preview to a commercial offering. OpenAI's press release cites partnerships with Novo Nordisk and Moderna, and the host stresses OpenAI is building tools for pharma, not becoming a biotech firm.